title: The use of a decremental dose regimen in patients treated with a chronic low-dose step-up protocol for WHO Group II anovulation: a prospective randomized multicentre study.
abstract: BACKGROUND
  In women with chronic anovulation, the choice of the FSH starting dose and the modality of subsequent dose adjustments are critical in controlling the risk of overstimulation. The aim of this prospective randomized study was to assess the efficacy and safety of a decremental FSH dose regimen applied once the leading follicle was 10-13 mm in diameter in women treated for WHO Group II anovulation according to a chronic low-dose (CLD; 75 IU FSH for 14 days with 37.5 IU increment) step-up protocol.
  
  
  METHODS
  Two hundred and nine subfertile women were treated with recombinant human FSH (r-hFSH) (Gonal-f) for ovulation induction according to a CLD step-up regimen. When the leading follicle reached a diameter of 10-13 mm, 158 participants were randomized by means of a computer-generated list to receive either the same FSH dose required to achieve the threshold for follicular development (CLD regimen) or half of this FSH dose [sequential (SQ) regimen]. HCG was administered only if not more than three follicles >or=16 mm in diameter were present and/or serum estradiol (E(2)) values were <1200 pg/ml. The primary outcome measure was the number of follicles >or=16 mm in size at the time of hCG administration.
  
  
  RESULTS
  Clinical characteristics and ovarian parameters at the time of randomization were similar in the two groups. Both CLD and SQ protocols achieved similar follicular growth as regards the total number of follicles and medium-sized or mature follicles (>/=16 mm: 1.5 +/- 0.9 versus 1.4 +/- 0.7, respectively). Furthermore, serum E(2) levels were equivalent in the two groups at the time of hCG administration (441 +/- 360 versus 425 +/- 480 pg/ml for CLD and SQ protocols, respectively). The rate of mono-follicular development was identical as well as the percentage of patients who ovulated and achieved pregnancy.
  
  
  CONCLUSIONS
  The results show that the CLD step-up regimen for FSH administration is efficacious and safe for promoting mono-follicular ovulation in women with WHO Group II anovulation. This study confirms that maintaining the same FSH starting dose for 14 days before increasing the dose in step-up regimen is critical to adequately control the risk of over-response. Strict application of CLD regimen should be recommended in women with WHO Group II anovulation.
authors.affiliation: Reproductive Medicine Unit, Jean Verdier Hospital, University Paris XIII, Paris, France. jean-noel.hugues@jvr.ap-hop-paris.fr
authors.forename: J N
authors.initials: JN
authors.lastname: Hugues
authors.forename: I
authors.initials: I
authors.lastname: Cédrin-Durnerin
authors.forename: C M
authors.initials: CM
authors.lastname: Howles
authors.forename: M
authors.initials: M
authors.lastname: Amram
authors.forename: A
authors.initials: A
authors.lastname: Angelini
authors.forename: A
authors.initials: A
authors.lastname: Balen
authors.forename: D
authors.initials: D
authors.lastname: Barbereau
authors.forename: M
authors.initials: M
authors.lastname: Birkhauser
authors.forename: A
authors.initials: A
authors.lastname: Boujenah
authors.forename: V
authors.initials: V
authors.lastname: De Leo
authors.forename: G
authors.initials: G
authors.lastname: De Placido
authors.forename: S
authors.initials: S
authors.lastname: Dessole
authors.forename: S
authors.initials: S
authors.lastname: Favrin
authors.forename: E
authors.initials: E
authors.lastname: Ferrazi
authors.forename: C
authors.initials: C
authors.lastname: Gay
authors.forename: M
authors.initials: M
authors.lastname: Germond
authors.forename: B
authors.initials: B
authors.lastname: Hedon
authors.forename: C
authors.initials: C
authors.lastname: Hocke
authors.forename: C
authors.initials: C
authors.lastname: Jolly
authors.forename: E
authors.initials: E
authors.lastname: Lamarca-Roth
authors.forename: A
authors.initials: A
authors.lastname: Lanzone
authors.forename: F
authors.initials: F
authors.lastname: Marchand
authors.forename: G
authors.initials: G
authors.lastname: Marcolin
authors.forename: G
authors.initials: G
authors.lastname: Mascaretti
authors.forename: L
authors.initials: L
authors.lastname: Moreau
authors.forename: M
authors.initials: M
authors.lastname: Massobrio
authors.forename: C
authors.initials: C
authors.lastname: Nappi
authors.forename: G
authors.initials: G
authors.lastname: Pardi
authors.forename: G
authors.initials: G
authors.lastname: Pennehouat
authors.forename: E
authors.initials: E
authors.lastname: Porcu
authors.forename: M
authors.initials: M
authors.lastname: Seibert
authors.forename: L
authors.initials: L
authors.lastname: Selvaggi
authors.forename: D
authors.initials: D
authors.lastname: Thiers
authors.forename: P
authors.initials: P
authors.lastname: Venturini
mesh_terms: D000858:Anovulation / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D043373:Follicle Stimulating Hormone, Human / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy; D018579:Patient Selection; D011247:Pregnancy; D011256:Pregnancy Outcome; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012449:Safety; D016896:Treatment Outcome
chemical_list: D043373:Follicle Stimulating Hormone, Human; D011994:Recombinant Proteins